Close Menu

NEW YORK (GenomeWeb) – Editas Medicine has exclusively licensed a newly released CRISPR enzyme from Integrated DNA Technologies for human therapeutic applications, IDT said today.

The new enzyme, Alt-R Cas12a (Cpf1) Ultra is a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1) that has enhanced editing activity, reaching or exceeding the performance of Cas9, according to IDT. The new enzyme also retains activity across a wider temperature range than the wild-type enzyme, making it useful for genome editing in additional organisms, including plants.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.